Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis

References

• Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408–427.
   PubMed Web of Science ®Google Scholar
• Said G, Ropert A, Faux N. Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: a clinicopathologic study. Neurology. 1984;34(8):1025–1032.
   PubMed Web of Science ®Google Scholar
• Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14–S26.
   PubMedGoogle Scholar
• Saraiva MJ, Birken S, Costa PP, et al. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest. 1984;74(1):104–119.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398–408.
   PubMed Web of Science ®Google Scholar
• Waddington-Cruz M, Schmidt H, Botteman MF, et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis. 2019;14(1):34.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Ueda M, Koike H, et al. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6.
   PubMed Web of Science ®Google Scholar
• Lemos C, Coelho T, Alves-Ferreira M, et al. Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry. 2014;85(3):326–330.
   PubMed Web of Science ®Google Scholar
• Santos D, Coelho T, Alves-Ferreira M, et al. Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). Eur J Hum Genet. 2016;24(5):756–760.
   PubMed Web of Science ®Google Scholar
• Santos D, Coelho T, Alves-Ferreira M, et al. Familial amyloid polyneuropathy in Portugal: new genes modulating age-at-onset. Ann Clin Transl Neurol. 2017;4(2):98–105.
   PubMed Web of Science ®Google Scholar
• Dias A, Santos D, Coelho T, et al. C1QA and C1QC modify age‐at‐onset in familial amyloid polyneuropathy patients. Ann Clin Transl Neurol. 2019;6(4):748–775.
   PubMed Web of Science ®Google Scholar
• Sikora JL, Logue MW, Chan GG, et al. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt). Hum Genet. 2015;134(1):111–121.
   PubMed Web of Science ®Google Scholar
• Alves-Ferreira M, Coelho T, Santos D, et al. A trans-acting factor may modify age at onset in familial amyloid polyneuropathy ATTRV30M in Portugal. Mol Neurobiol. 2018;55(5):3676–3683.
   PubMed Web of Science ®Google Scholar
• Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009;37(Web Server issue):W600–605.
   PubMed Web of Science ®Google Scholar
• Khan A, Fornes O, Stigliani A, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 2018;46(D1):D260–D266.
   PubMed Web of Science ®Google Scholar
• Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12(8):697.
   PubMed Web of Science ®Google Scholar
• Kertesz M, Iovino N, Unnerstall U, et al. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278–1284.
   PubMed Web of Science ®Google Scholar
• Coelho T, Chorão R, Sousa A, et al. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscular Disorders. 1996;6(Suppl 1):S20.
   Google Scholar
• Fitch NJ, Akbari MT, Ramsden DB. An inherited non-amyloidogenic transthyretin variant, [Ser6]-TTR, with increased thyroxine-binding affinity, characterized by DNA sequencing. J Endocrinol. 1991;129(2):309–313.
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299(5607):713–716.
   PubMed Web of Science ®Google Scholar
• Holmgren G, Hellman U, Lundgren HE, et al. Impact of homozygosity for an amyloidogenic transthyretin mutation on phenotype and long term outcome. J Med Genet. 2005;42(12):953–956.
   PubMed Web of Science ®Google Scholar
• Yoshinaga T, Nakazato M, Ikeda S, et al. Homozygosity for the transthyretin-Met30 gene in three Japanese siblings with type I familial amyloidotic polyneuropathy. Neurology. 1992;42(10):2045–2047.
   PubMed Web of Science ®Google Scholar
• Mellerup E, Moller GL. Combinations of genetic variants occurring exclusively in patients. Comput Struct Biotechnol J. 2017;15:286–289.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Bi R, Xu M, et al. Rare genetic variants of the transthyretin gene are associated with Alzheimer's disease in Han Chinese. Mol Neurobiol. 2017;54(7):5192–5200.
   PubMed Web of Science ®Google Scholar
• Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002;3(4):285–298.
   PubMed Web of Science ®Google Scholar
• Wang Z, Burke PA. Hepatocyte nuclear factor-4α interacts with other hepatocyte nuclear factors in regulating transthyretin gene expression. Febs J. 2010;277(19):4066–4075.
   PubMed Web of Science ®Google Scholar
• Lambert M, Jambon S, Depauw S, et al. Targeting transcription factors for cancer treatment. Molecules. 2018;23(6):1479.
   PubMed Web of Science ®Google Scholar
• Butt TR, Karathanasis SK. Transcription factors as drug targets: opportunities for therapeutic selectivity. Gene Expr. 1995;4(6):319–336.
   PubMed Web of Science ®Google Scholar
• Saha S, Chakraborty S, Bhattacharya A, et al. MicroRNA regulation of transthyretin in trophoblast differentiation and Intra-uterine growth restriction. Sci Rep. 2017;7(1):16548.
   PubMedGoogle Scholar
• Alnylam PI. Onpattro (patisiran) lipid complex injection, for intravenous use: US prescribing information; 2018 [Accessed 2018 Oct 4]. http://www.fda.gov/.
   Google Scholar
• EU. EMA-E. Tegsedi International non-proprietary name: inotersen. Assessment report; 2018 [cited 2018 May 31].
   Google Scholar
• Mercatante DR, Kole R. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. Biochim Biophys Acta. 2002;1587(2–3):126–132.
   PubMed Web of Science ®Google Scholar
• Ruger J, Ioannou S, Castanotto D, et al. Oligonucleotides to the (gene) rescue: FDA approvals 2017-2019. Trends Pharmacol Sci. 2020;41(1):27–41.
   PubMed Web of Science ®Google Scholar